main content start
Merck
Banting Circle Supporters
Merck supported phase 3 of ADA’s Overcoming Therapeutic Inertia program. The main goal of phase 3 was to promote the measurable adoption of evidence-based practices, strategies, programs, and tools that address key barriers associated with therapeutic inertia in diabetes care, leading to improved, timely treatment modification and improved overall glycemic control in adult patients with type 2 diabetes.
Give Today and Change lives!
With your support, the American Diabetes Association® can continue our lifesaving work to make breakthroughs in research and provide people with the resources they need to fight diabetes.